RPR Gencell reshuffles its cards

RPR Gencell reshuffles its cards

Rhone-Poulenc Rorer Inc. is using the flexibility of its RPR Gencell division to reshuffle its gene therapy bets, de-emphasizing ex vivo therapy and bringing in more of the latest in genomics and other drug discovery technologies.

The latest move

Read the full 438 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE